Sugi Predict

Sugi Predict / Compounds / SCHEMBL19084308

SCHEMBL19084308

SCHEMBL19084308

C=C(C)[C@H](NC(=O)CCC(=O)N1CCC(C(=O)O)CC1)C(=O)N[C@@H](CCCNC(N)=O)C(=O)Nc1ccc(C[C@@H](CN)NC(=O)[C@H](C)[C@@H](OC)[C@@H]2CCCN2C(=O)C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C)cc1

nearest known ligand 0.46

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 1/20 0.46
▸ FOLH1 Q04609 3/20 0.46
▸ TTR P02766 2/20 0.41
▸ SSTR2 P30874 2/20 0.36
▸ NECTIN4 Q96NY8 1/20 0.33
▸ FAP Q12884 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19084307 0.95 CYP3A4 (0.49) CYP3A4FOLH1TTRSSTR2NECTIN4
SCHEMBL19084353 0.95 CYP3A4 (0.49) CYP3A4FOLH1TTRSSTR2NECTIN4
SCHEMBL20846180 0.91 CYP3A4 (0.48) CYP3A4FOLH1TTRSSTR2NECTIN4
SCHEMBL20846239 0.91 CYP3A4 (0.48) CYP3A4FOLH1TTRSSTR2NECTIN4
SCHEMBL17987755 0.89 CYP3A4 (0.48) CYP3A4FOLH1TTRSSTR2NECTIN4
SCHEMBL20800166 0.89 CYP3A4 (0.48) CYP3A4FOLH1TTRSSTR2NECTIN4
SCHEMBL26270646 0.89 CYP3A4 (0.47) CYP3A4FOLH1TTRSSTR2NECTIN4
SCHEMBL22068458 0.88 CYP3A4 (0.53) CYP3A4FOLH1TTRSSTR2NECTIN4
SCHEMBL22068086 0.88 CYP3A4 (0.52) CYP3A4FOLH1TTRSSTR2NECTIN4
SCHEMBL20846080 0.88 CYP3A4 (0.44) CYP3A4FOLH1TTRSSTR2NECTIN4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10590165-B2 Antibody drug conjugates SORRENTO THERAPEUTICS, INC. (US) 2020-03-17 — — US disclosed
US-20170190736-A1 Antibody Drug Conjugates SORRENTO THERAPEUTICS, INC. (US) 2017-07-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10590165-B2 Antibody drug conjugates STT3B, STT3A, HSD17B14 CYP3A4 49/4885FOLH1 392/4885TTR 3617/4885
US-20170190736-A1 Antibody Drug Conjugates STT3B, STT3A, HSD17B14 CYP3A4 49/4885FOLH1 392/4885TTR 3617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.